Global Scleroderma Treatment Market

Scleroderma Treatment Comprehensive Study by Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, Systemic Sclerosis Sine Scleroderma), Drug (Immunosuppressors, Calcium Channel Blockers, Proton Pump Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists, Prostacyclin Analogues, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Route (Oral, Parenteral) Players and Region - Global Market Outlook to 2027

Scleroderma Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Scleroderma Treatment typically focuses on inflammation, autoimmunity, vascular issues, and tissue fibrosis, which is defined as the thickening and scarring of the connective tissue that surrounds internal organs. Using nonsteroidal anti-inflammatory drugs or corticosteroids to relieve pain. Skin lotions and moisturizers can help relieve skin itchiness. Slowing skin thickening and minimizing damage to internal organs with immune suppressant medication. Scleroderma is a group of autoimmune diseases that can cause skin, blood vessels, muscle, and internal organ changes. The disease can be limited to the skin or spread to other organs. With cold exposure, symptoms may include thickened skin, stiffness, fatigue, and poor blood flow to the fingers or toes. CREST syndrome is a type of condition that causes calcium deposits, Raynaud's syndrome, esophageal problems, thickening of the skin on the fingers and toes, and areas of small, dilated blood vessels.This growth is primarily driven by Need to Treat Scleroderma In Order To Improve Patient Life Is Driving Market Growth .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitN
Value UnitValue (USD Million)
Key Companies in StudyBristol-Myers Squibb Company (United States), Boehringer Ingelheim International GmbH (United States), Allergan (United States), Actelion Pharmaceuticals Ltd (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (United Kingdom), Biogen (United States), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel) and AstraZeneca (United Kingdom)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Facilities sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Bristol-Myers Squibb Company (United States), Boehringer Ingelheim International GmbH (United States), Allergan (United States), Actelion Pharmaceuticals Ltd (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (United Kingdom), Biogen (United States), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel) and AstraZeneca (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 9th September 2021, Sanofi has entered into a merger agreement with Kadmon, which is developing belumosudil (KD025), an oral investigational treatment for people with the diffuse cutaneous form of systemic sclerosis (dcSSc).
On 25th January 2022, Paracrine, Inc. announced that the FDA has granted full approval of its Investigational Device Exemption (IDE) to conduct a pivotal trial titled Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells.In the global scleroderma treatment market, the top major competitors are investing in capacity, market shares, and recent events. The market for systemic scleroderma treatments is highly competitive due to the large number of unmet medical needs. Large corporations in the systemic scleroderma treatment industry are pursuing growth strategies such as mergers and acquisitions, partnerships, and strategic alliances.

Regulatory Insights:
NDCP only applies to patients with SSc and is limited to the form specified in the text of current ALD regulations. It was decided that this NDCP would not include localised sclerodermas, also known as morphea, which are sclerotic attacks of the skin that are usually limited to it but can occasionally extend to the underlying muscle, bone, and nerve tissues without causing systemic symptoms.

Market Drivers
  • Need to Treat Scleroderma In Order To Improve Patient Life Is Driving Market Growth
  • There Is an Increased Demand for Scleroderma Treatment to Slow Skin Thickening and Reduce the Impact on Internal Organs

Market Trend
  • Current Discoveries in the Pathogenesis of Scleroderma Are Expected To Revolutionize Traditional Treatment

Restraints
  • Side Effects of PABA, Colchicine, D-Penicillamine, or Dimethyl Sulfoxide in Treatment May Stymie the Growth of the Scleroderma Treatment Market

Opportunities
Advancement in Medicine for More Effective Treatment May Provide Further Growth Avenues Will Propel the Scleroderma Treatment Market and The Development of First-In-Class Curatives That Are Under Clinical Trials Is Expected To Boost the Scleroderma Treatment Market
Challenges
High Cost of Obtaining Scleroderma Treatment Will Impede the Scleroderma Treatment Market's Wide Adoption among Lower Income Group Patients

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Scleroderma Treatment Study Sheds Light on
— The Scleroderma Treatment Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Scleroderma Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Scleroderma Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Limited Systemic Sclerosis
  • Diffused Systemic Sclerosis
  • Systemic Sclerosis Sine Scleroderma
By Drug
  • Immunosuppressors
  • Calcium Channel Blockers
  • Proton Pump Inhibitors
  • Phosphodiesterase 5 Inhibitors
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Route
  • Oral
  • Parenteral

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Need to Treat Scleroderma In Order To Improve Patient Life Is Driving Market Growth
      • 3.2.2. There Is an Increased Demand for Scleroderma Treatment to Slow Skin Thickening and Reduce the Impact on Internal Organs
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Obtaining Scleroderma Treatment Will Impede the Scleroderma Treatment Market's Wide Adoption among Lower Income Group Patients
    • 3.4. Market Trends
      • 3.4.1. Current Discoveries in the Pathogenesis of Scleroderma Are Expected To Revolutionize Traditional Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Scleroderma Treatment, by Type, Drug, Distribution Channel, Route and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Scleroderma Treatment (Value)
      • 5.2.1. Global Scleroderma Treatment by: Type (Value)
        • 5.2.1.1. Limited Systemic Sclerosis
        • 5.2.1.2. Diffused Systemic Sclerosis
        • 5.2.1.3. Systemic Sclerosis Sine Scleroderma
      • 5.2.2. Global Scleroderma Treatment by: Drug (Value)
        • 5.2.2.1. Immunosuppressors
        • 5.2.2.2. Calcium Channel Blockers
        • 5.2.2.3. Proton Pump Inhibitors
        • 5.2.2.4. Phosphodiesterase 5 Inhibitors
        • 5.2.2.5. Endothelin Receptor Antagonists
        • 5.2.2.6. Prostacyclin Analogues
        • 5.2.2.7. Others
      • 5.2.3. Global Scleroderma Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Scleroderma Treatment by: Route (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Parenteral
      • 5.2.5. Global Scleroderma Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Scleroderma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim International GmbH (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Actelion Pharmaceuticals Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biogen (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Scleroderma Treatment Sale, by Type, Drug, Distribution Channel, Route and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Scleroderma Treatment (Value)
      • 7.2.1. Global Scleroderma Treatment by: Type (Value)
        • 7.2.1.1. Limited Systemic Sclerosis
        • 7.2.1.2. Diffused Systemic Sclerosis
        • 7.2.1.3. Systemic Sclerosis Sine Scleroderma
      • 7.2.2. Global Scleroderma Treatment by: Drug (Value)
        • 7.2.2.1. Immunosuppressors
        • 7.2.2.2. Calcium Channel Blockers
        • 7.2.2.3. Proton Pump Inhibitors
        • 7.2.2.4. Phosphodiesterase 5 Inhibitors
        • 7.2.2.5. Endothelin Receptor Antagonists
        • 7.2.2.6. Prostacyclin Analogues
        • 7.2.2.7. Others
      • 7.2.3. Global Scleroderma Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Scleroderma Treatment by: Route (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Parenteral
      • 7.2.5. Global Scleroderma Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Scleroderma Treatment: by Type(USD Million)
  • Table 2. Scleroderma Treatment Limited Systemic Sclerosis , by Region USD Million (2016-2021)
  • Table 3. Scleroderma Treatment Diffused Systemic Sclerosis , by Region USD Million (2016-2021)
  • Table 4. Scleroderma Treatment Systemic Sclerosis Sine Scleroderma , by Region USD Million (2016-2021)
  • Table 5. Scleroderma Treatment: by Drug(USD Million)
  • Table 6. Scleroderma Treatment Immunosuppressors , by Region USD Million (2016-2021)
  • Table 7. Scleroderma Treatment Calcium Channel Blockers , by Region USD Million (2016-2021)
  • Table 8. Scleroderma Treatment Proton Pump Inhibitors , by Region USD Million (2016-2021)
  • Table 9. Scleroderma Treatment Phosphodiesterase 5 Inhibitors , by Region USD Million (2016-2021)
  • Table 10. Scleroderma Treatment Endothelin Receptor Antagonists , by Region USD Million (2016-2021)
  • Table 11. Scleroderma Treatment Prostacyclin Analogues , by Region USD Million (2016-2021)
  • Table 12. Scleroderma Treatment Others , by Region USD Million (2016-2021)
  • Table 13. Scleroderma Treatment: by Distribution Channel(USD Million)
  • Table 14. Scleroderma Treatment Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 15. Scleroderma Treatment Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 16. Scleroderma Treatment Online Pharmacies , by Region USD Million (2016-2021)
  • Table 17. Scleroderma Treatment: by Route(USD Million)
  • Table 18. Scleroderma Treatment Oral , by Region USD Million (2016-2021)
  • Table 19. Scleroderma Treatment Parenteral , by Region USD Million (2016-2021)
  • Table 20. South America Scleroderma Treatment, by Country USD Million (2016-2021)
  • Table 21. South America Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 22. South America Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 23. South America Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 24. South America Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 25. Brazil Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 26. Brazil Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 27. Brazil Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 28. Brazil Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 29. Argentina Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 30. Argentina Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 31. Argentina Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 32. Argentina Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 33. Rest of South America Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 35. Rest of South America Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 36. Rest of South America Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 37. Asia Pacific Scleroderma Treatment, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 40. Asia Pacific Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 41. Asia Pacific Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 42. China Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 43. China Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 44. China Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 45. China Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 46. Japan Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 47. Japan Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 48. Japan Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 49. Japan Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 50. India Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 51. India Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 52. India Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 53. India Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 54. South Korea Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 55. South Korea Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 56. South Korea Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 57. South Korea Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 58. Australia Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 59. Australia Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 60. Australia Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 61. Australia Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 66. Europe Scleroderma Treatment, by Country USD Million (2016-2021)
  • Table 67. Europe Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 68. Europe Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 69. Europe Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 70. Europe Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 71. Germany Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 72. Germany Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 73. Germany Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 74. Germany Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 75. France Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 76. France Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 77. France Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 78. France Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 79. Italy Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 80. Italy Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 81. Italy Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 82. Italy Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 83. United Kingdom Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 84. United Kingdom Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 85. United Kingdom Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 86. United Kingdom Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 87. Netherlands Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 88. Netherlands Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 89. Netherlands Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 90. Netherlands Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 91. Rest of Europe Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 92. Rest of Europe Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 93. Rest of Europe Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 94. Rest of Europe Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 95. MEA Scleroderma Treatment, by Country USD Million (2016-2021)
  • Table 96. MEA Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 97. MEA Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 98. MEA Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 99. MEA Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 100. Middle East Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 101. Middle East Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 102. Middle East Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 103. Middle East Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 104. Africa Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 105. Africa Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 106. Africa Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 107. Africa Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 108. North America Scleroderma Treatment, by Country USD Million (2016-2021)
  • Table 109. North America Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 110. North America Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 111. North America Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 112. North America Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 113. United States Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 114. United States Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 115. United States Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 116. United States Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 117. Canada Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 118. Canada Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 119. Canada Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 120. Canada Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 121. Mexico Scleroderma Treatment, by Type USD Million (2016-2021)
  • Table 122. Mexico Scleroderma Treatment, by Drug USD Million (2016-2021)
  • Table 123. Mexico Scleroderma Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 124. Mexico Scleroderma Treatment, by Route USD Million (2016-2021)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Scleroderma Treatment: by Type(USD Million)
  • Table 136. Scleroderma Treatment Limited Systemic Sclerosis , by Region USD Million (2022-2027)
  • Table 137. Scleroderma Treatment Diffused Systemic Sclerosis , by Region USD Million (2022-2027)
  • Table 138. Scleroderma Treatment Systemic Sclerosis Sine Scleroderma , by Region USD Million (2022-2027)
  • Table 139. Scleroderma Treatment: by Drug(USD Million)
  • Table 140. Scleroderma Treatment Immunosuppressors , by Region USD Million (2022-2027)
  • Table 141. Scleroderma Treatment Calcium Channel Blockers , by Region USD Million (2022-2027)
  • Table 142. Scleroderma Treatment Proton Pump Inhibitors , by Region USD Million (2022-2027)
  • Table 143. Scleroderma Treatment Phosphodiesterase 5 Inhibitors , by Region USD Million (2022-2027)
  • Table 144. Scleroderma Treatment Endothelin Receptor Antagonists , by Region USD Million (2022-2027)
  • Table 145. Scleroderma Treatment Prostacyclin Analogues , by Region USD Million (2022-2027)
  • Table 146. Scleroderma Treatment Others , by Region USD Million (2022-2027)
  • Table 147. Scleroderma Treatment: by Distribution Channel(USD Million)
  • Table 148. Scleroderma Treatment Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 149. Scleroderma Treatment Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 150. Scleroderma Treatment Online Pharmacies , by Region USD Million (2022-2027)
  • Table 151. Scleroderma Treatment: by Route(USD Million)
  • Table 152. Scleroderma Treatment Oral , by Region USD Million (2022-2027)
  • Table 153. Scleroderma Treatment Parenteral , by Region USD Million (2022-2027)
  • Table 154. South America Scleroderma Treatment, by Country USD Million (2022-2027)
  • Table 155. South America Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 156. South America Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 157. South America Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 158. South America Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 159. Brazil Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 160. Brazil Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 161. Brazil Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 162. Brazil Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 163. Argentina Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 164. Argentina Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 165. Argentina Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 166. Argentina Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 167. Rest of South America Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 168. Rest of South America Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 169. Rest of South America Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 170. Rest of South America Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 171. Asia Pacific Scleroderma Treatment, by Country USD Million (2022-2027)
  • Table 172. Asia Pacific Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 173. Asia Pacific Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 174. Asia Pacific Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 175. Asia Pacific Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 176. China Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 177. China Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 178. China Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 179. China Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 180. Japan Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 181. Japan Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 182. Japan Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 183. Japan Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 184. India Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 185. India Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 186. India Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 187. India Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 188. South Korea Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 189. South Korea Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 190. South Korea Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 191. South Korea Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 192. Australia Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 193. Australia Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 194. Australia Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 195. Australia Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 196. Rest of Asia-Pacific Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 200. Europe Scleroderma Treatment, by Country USD Million (2022-2027)
  • Table 201. Europe Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 202. Europe Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 203. Europe Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 204. Europe Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 205. Germany Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 206. Germany Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 207. Germany Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 208. Germany Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 209. France Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 210. France Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 211. France Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 212. France Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 213. Italy Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 214. Italy Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 215. Italy Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 216. Italy Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 217. United Kingdom Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 218. United Kingdom Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 219. United Kingdom Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 220. United Kingdom Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 221. Netherlands Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 222. Netherlands Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 223. Netherlands Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 224. Netherlands Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 225. Rest of Europe Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 226. Rest of Europe Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 227. Rest of Europe Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 228. Rest of Europe Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 229. MEA Scleroderma Treatment, by Country USD Million (2022-2027)
  • Table 230. MEA Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 231. MEA Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 232. MEA Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 233. MEA Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 234. Middle East Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 235. Middle East Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 236. Middle East Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 237. Middle East Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 238. Africa Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 239. Africa Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 240. Africa Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 241. Africa Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 242. North America Scleroderma Treatment, by Country USD Million (2022-2027)
  • Table 243. North America Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 244. North America Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 245. North America Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 246. North America Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 247. United States Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 248. United States Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 249. United States Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 250. United States Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 251. Canada Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 252. Canada Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 253. Canada Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 254. Canada Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 255. Mexico Scleroderma Treatment, by Type USD Million (2022-2027)
  • Table 256. Mexico Scleroderma Treatment, by Drug USD Million (2022-2027)
  • Table 257. Mexico Scleroderma Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 258. Mexico Scleroderma Treatment, by Route USD Million (2022-2027)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Scleroderma Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Scleroderma Treatment: by Drug USD Million (2016-2021)
  • Figure 6. Global Scleroderma Treatment: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global Scleroderma Treatment: by Route USD Million (2016-2021)
  • Figure 8. South America Scleroderma Treatment Share (%), by Country
  • Figure 9. Asia Pacific Scleroderma Treatment Share (%), by Country
  • Figure 10. Europe Scleroderma Treatment Share (%), by Country
  • Figure 11. MEA Scleroderma Treatment Share (%), by Country
  • Figure 12. North America Scleroderma Treatment Share (%), by Country
  • Figure 13. Global Scleroderma Treatment share by Players 2021 (%)
  • Figure 14. Global Scleroderma Treatment share by Players (Top 3) 2021(%)
  • Figure 15. Global Scleroderma Treatment share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 19. Boehringer Ingelheim International GmbH (United States) Revenue, Net Income and Gross profit
  • Figure 20. Boehringer Ingelheim International GmbH (United States) Revenue: by Geography 2021
  • Figure 21. Allergan (United States) Revenue, Net Income and Gross profit
  • Figure 22. Allergan (United States) Revenue: by Geography 2021
  • Figure 23. Actelion Pharmaceuticals Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Actelion Pharmaceuticals Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 25. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 27. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 29. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 30. Biogen (United States) Revenue: by Geography 2021
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 33. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 35. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 37. Global Scleroderma Treatment: by Type USD Million (2022-2027)
  • Figure 38. Global Scleroderma Treatment: by Drug USD Million (2022-2027)
  • Figure 39. Global Scleroderma Treatment: by Distribution Channel USD Million (2022-2027)
  • Figure 40. Global Scleroderma Treatment: by Route USD Million (2022-2027)
  • Figure 41. South America Scleroderma Treatment Share (%), by Country
  • Figure 42. Asia Pacific Scleroderma Treatment Share (%), by Country
  • Figure 43. Europe Scleroderma Treatment Share (%), by Country
  • Figure 44. MEA Scleroderma Treatment Share (%), by Country
  • Figure 45. North America Scleroderma Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb Company (United States)
  • Boehringer Ingelheim International GmbH (United States)
  • Allergan (United States)
  • Actelion Pharmaceuticals Ltd (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • GlaxoSmithKline plc. (United Kingdom)
  • Biogen (United States)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • AstraZeneca (United Kingdom)
Additional players considered in the study are as follows:
Celgene Corporation (United States) , Ono pharmaceutical co. Ltd (Japan) , Aspen Holdings (South Africa) , Others
Select User Access Type

Key Highlights of Report


Jul 2022 204 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Scleroderma Treatment Market Quantitative research analysis
Global Scleroderma Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Scleroderma Treatment Market are Bristol-Myers Squibb Company (United States), Boehringer Ingelheim International GmbH (United States), Allergan (United States), Actelion Pharmaceuticals Ltd (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (United Kingdom), Biogen (United States), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel) and AstraZeneca (United Kingdom) etc.
AMA Research predicts that United States Players will contribute to the maximum growth of Global Scleroderma Treatment market throughout the forecasted period.

Know More About Global Scleroderma Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Home Hemodialysis Comprehensive Study by Type (Hemodialysis, Peritoneal Dialysis, Device, Consumables, Others), Application (Drug Store, On-line), Treatment (Acute Kidney Disease, Chronic Kidney Dise...
$ 3800
Oncology Clinical Trials Comprehensive Study by Design (Observational Studies, Treatment Studies), Phase (Phase I, Phase II, Phase III), Cancer (Lung Cancer, Breast Cancer, Thyroid Cancer, Leukemia, ...
$ 3500
Systemic Lupus Erythematosus Treatment Comprehensive Study by Type (Hydroxychloroquine, Nonsteroidal Anti-Inflammatory Medications (NSAIDS), Steroids), End users (Hospitals, Clinics, Others), Body Pa...
$ 3800